An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents

Sumio Matzno, Yuka Yamaguchi, Takeshi Akiyoshi, Toshikatsu Nakabayashi, Kenji Matsuyama

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The possibility of vitamin K3 (VK3) as an anticancer agent was assessed. VK3 dose-dependently diminished the cell viability (measured as esterase activity) with IC50 of 13.7 μM and Hill coefficient of 3.1 in Hep G2 cells. It also decreased the population of S phase and arrested cell cycle in the G2/M phase in a dose-dependent manner. G2/M arrest was regulated by the increment of cyclin A/cdk1 and cyclin A/cdk2 complex, and contrasting cyclin B/cdk1 complex decrease. Finally, combined application demonstrated that VK3 significantly enhanced the cytotoxicity of etoposide, a G2 phase-dependent anticancer agent, whereas it reduced the cytotoxic activity of irinotecan, a S phase-dependent agent. These findings suggest that VK3 induces G 2/M arrest by inhibition of cyclin B/cdk1 complex formation, and is thus useful as an enhancer of G2 phase-dependent drugs in hepatic cancer chemotherapy.

Original languageEnglish
Pages (from-to)1270-1273
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume31
Issue number6
DOIs
Publication statusPublished - 2008 Jun
Externally publishedYes

Fingerprint

Vitamin K 3
Antineoplastic Agents
G2 Phase
Cyclin B
Cyclin A
irinotecan
S Phase
Hep G2 Cells
Etoposide
Esterases
Liver Neoplasms
Cell Division
Inhibitory Concentration 50
Cell Survival
Cell Cycle
Drug Therapy
Pharmaceutical Preparations
Population

Keywords

  • Etoposide
  • G/M arrest
  • Hepatic cancer
  • Vitamin K

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. / Matzno, Sumio; Yamaguchi, Yuka; Akiyoshi, Takeshi; Nakabayashi, Toshikatsu; Matsuyama, Kenji.

In: Biological and Pharmaceutical Bulletin, Vol. 31, No. 6, 06.2008, p. 1270-1273.

Research output: Contribution to journalArticle

Matzno, Sumio ; Yamaguchi, Yuka ; Akiyoshi, Takeshi ; Nakabayashi, Toshikatsu ; Matsuyama, Kenji. / An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. In: Biological and Pharmaceutical Bulletin. 2008 ; Vol. 31, No. 6. pp. 1270-1273.
@article{8311f546fa444dfa9e7048d87a85f324,
title = "An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents",
abstract = "The possibility of vitamin K3 (VK3) as an anticancer agent was assessed. VK3 dose-dependently diminished the cell viability (measured as esterase activity) with IC50 of 13.7 μM and Hill coefficient of 3.1 in Hep G2 cells. It also decreased the population of S phase and arrested cell cycle in the G2/M phase in a dose-dependent manner. G2/M arrest was regulated by the increment of cyclin A/cdk1 and cyclin A/cdk2 complex, and contrasting cyclin B/cdk1 complex decrease. Finally, combined application demonstrated that VK3 significantly enhanced the cytotoxicity of etoposide, a G2 phase-dependent anticancer agent, whereas it reduced the cytotoxic activity of irinotecan, a S phase-dependent agent. These findings suggest that VK3 induces G 2/M arrest by inhibition of cyclin B/cdk1 complex formation, and is thus useful as an enhancer of G2 phase-dependent drugs in hepatic cancer chemotherapy.",
keywords = "Etoposide, G/M arrest, Hepatic cancer, Vitamin K",
author = "Sumio Matzno and Yuka Yamaguchi and Takeshi Akiyoshi and Toshikatsu Nakabayashi and Kenji Matsuyama",
year = "2008",
month = "6",
doi = "10.1248/bpb.31.1270",
language = "English",
volume = "31",
pages = "1270--1273",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "6",

}

TY - JOUR

T1 - An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents

AU - Matzno, Sumio

AU - Yamaguchi, Yuka

AU - Akiyoshi, Takeshi

AU - Nakabayashi, Toshikatsu

AU - Matsuyama, Kenji

PY - 2008/6

Y1 - 2008/6

N2 - The possibility of vitamin K3 (VK3) as an anticancer agent was assessed. VK3 dose-dependently diminished the cell viability (measured as esterase activity) with IC50 of 13.7 μM and Hill coefficient of 3.1 in Hep G2 cells. It also decreased the population of S phase and arrested cell cycle in the G2/M phase in a dose-dependent manner. G2/M arrest was regulated by the increment of cyclin A/cdk1 and cyclin A/cdk2 complex, and contrasting cyclin B/cdk1 complex decrease. Finally, combined application demonstrated that VK3 significantly enhanced the cytotoxicity of etoposide, a G2 phase-dependent anticancer agent, whereas it reduced the cytotoxic activity of irinotecan, a S phase-dependent agent. These findings suggest that VK3 induces G 2/M arrest by inhibition of cyclin B/cdk1 complex formation, and is thus useful as an enhancer of G2 phase-dependent drugs in hepatic cancer chemotherapy.

AB - The possibility of vitamin K3 (VK3) as an anticancer agent was assessed. VK3 dose-dependently diminished the cell viability (measured as esterase activity) with IC50 of 13.7 μM and Hill coefficient of 3.1 in Hep G2 cells. It also decreased the population of S phase and arrested cell cycle in the G2/M phase in a dose-dependent manner. G2/M arrest was regulated by the increment of cyclin A/cdk1 and cyclin A/cdk2 complex, and contrasting cyclin B/cdk1 complex decrease. Finally, combined application demonstrated that VK3 significantly enhanced the cytotoxicity of etoposide, a G2 phase-dependent anticancer agent, whereas it reduced the cytotoxic activity of irinotecan, a S phase-dependent agent. These findings suggest that VK3 induces G 2/M arrest by inhibition of cyclin B/cdk1 complex formation, and is thus useful as an enhancer of G2 phase-dependent drugs in hepatic cancer chemotherapy.

KW - Etoposide

KW - G/M arrest

KW - Hepatic cancer

KW - Vitamin K

UR - http://www.scopus.com/inward/record.url?scp=45749097057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749097057&partnerID=8YFLogxK

U2 - 10.1248/bpb.31.1270

DO - 10.1248/bpb.31.1270

M3 - Article

C2 - 18520067

AN - SCOPUS:45749097057

VL - 31

SP - 1270

EP - 1273

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 6

ER -